Join the Oncology Voice Network. Join for Free
Best Practices and Creative Ways to Gain KOL Access During COVID-19
Provide 5 SEO Keywords separated by commas

Best Practices and Creative Ways to Gain KOL Access During COVID-19


Share This Article


Summary

In this episode, Tom Caravela speaks with Jason Demuth about his journey from retail pharmacy to the pharmaceutical industry. Jason shares his experiences engaging Key Opinion Leaders (KOLs) during COVID, emphasizing the strategic use of social media and email communication. The discussion explores the future of KOL access and offers strategies for aspiring MSLs. Jason compares roles in big pharma versus small pharma and highlights the importance of networking and recruiters in advancing MSL careers. The episode concludes with Jason's final thoughts and advice, alongside a call for listener engagement.

My guest today is Jason Demuth, Director, Medical Science Liaison at Strongbridge Bio shares creative ways to reach and access KOLs during COVID-19. 

In this episode we discuss:

  • Jason’s background
  • His journey and getting his first MSL role
  • Creative ideas and ways to access KOLs
  • His perspective on LinkedIn and Facebook for KOL engagement
  • Email interaction with KOLs
  • What is the future going to look like in terms of access in Jason’s perspective
  • His advice for new MSLs or those breaking into the role
  • Jason’s  advice for MSLs and/or MSL Leaders as we look to the future

Click for Source
Provide 5 SEO Keywords separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN